Market accessOfficial

SÚKL publishes list of non-reimbursed medicines on Czech market, valid from 1 November 2026

🇨🇿 SÚKL · Tue 27 Oct 2026

The Czech regulator's list covers registered products traded between April and September 2026 that receive no public health insurance reimbursement, plus certain products with a set maximum price.

The State Institute for Drug Control (SÚKL) in the Czech Republic published on 27 October 2026 its list of medicinal products not reimbursed from public health insurance, valid as of 1 November 2026. The list was issued by the agency's department supporting supervisory activities.

It covers registered medicinal products, and products in an approved specific treatment programme, that were actively marketed between April and September 2026 and are not reimbursed. Products with registration status R, B and F are included. Several ATC groups are excluded: blood substitutes and infusion or perfusion solutions (B05), contrast agents (V08), diagnostic radiopharmaceuticals (V09), therapeutic radiopharmaceuticals (V10) and homeopathics (V12).

The list also includes, regardless of whether they were on the market, medicinal products and foods for special medical purposes for which SÚKL has set a maximum price in defined situations under the Ministry of Health's pricing regulation. These include products used in both inpatient and ambulatory care that have no reimbursement for ambulatory use, such as those with health insurer consent, orphan medicines and advanced therapy products. They also include products where a insurer has asked for a maximum price while a request under section 19(3) of the public health insurance act is assessed. Further cases are highly innovative medicines whose temporary reimbursement has expired while proceedings on a further temporary or permanent reimbursement are not yet enforceable, and products whose pricing and reimbursement decision was appealed and returned in part to the Ministry of Health for reconsideration.

For these products the code list gives the maximum price, a reference to the administrative proceeding in which it was set, and the legal basis. The files are provided in XLS and TXT formats, with auxiliary code lists and a PDF description of the data interface, version 21. The interface corresponds to that of the price and reimbursement list valid from 1 January 2026.

What it means for your team

  • Market-access and pricing teams in the Czech Republic can use the list to check the non-reimbursed status of marketed products and any maximum prices set by SÚKL.
  • Products in the listed excluded ATC groups, including homeopathics and radiopharmaceuticals, will not appear, so absence from the list does not by itself show reimbursement.
  • Teams that load the data into internal systems should check the version 21 interface description and auxiliary code lists.
  • The publication has no direct safety or pharmacovigilance implications.

Official source: SÚKL ↗

Article written by VigiEye from the official source (SÚKL). AI-assisted; check the source before acting.

More Market access All →